-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoSTAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned compared to a similar analysis from a year...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agouniQure stock crashes as Huntington’s gene therapy data weaken
uniQure’s Huntington’s disease gene therapy has failed to significantly slow disease progression after 48 months, sending the biotech’s stock down 41% when trading began. But mitigating...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoCAR T start-up Link Cell names BMS, SystImmune vet Jie D’Elia CEO
BIOCENTURY | MANAGEMENT TRACKSCAR T START-UP LINK CELL NAMES BMS, SYSTIMMUNE VET JIE D’ELIA CEOIovance alum Friedrich Graf Finckenstein is CMO, co-founder Brian Slingerland becomes Executive Chair
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoWhen microbial DNA is scarce, new profiling method helps separate genuine signals from contamination
In acute, life-threatening infections, rapidly characterizing the microorganisms in a patient sample can help guide diagnosis and treatment. Computational methods known as taxonomic profilers can analyze...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoAn ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus.
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoLipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing
Nature Biotechnology, Published online: 28 September 2026; doi:10.1038/s41587-026-03298-8Lipid nanoparticles are improved by including RNA cargo size in the design process.
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoAuthor Correction: Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
Nature Biotechnology, Published online: 28 September 2026; doi:10.1038/s41587-026-03342-7Author Correction: Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoEngineered mini CRISPR enzyme gets a 60-fold power boost for gene editing
A tiny molecular scissor that once barely worked in human cells has been transformed into a high-performance genome-editing platform, thanks to a clever engineering strategy that...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoAdicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
As the race to harness CAR-T cells for autoimmune diseases hits a rough patch, a Bay Area biotech is gliding over the potholes with an early...
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoNew CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages
A CRISPR-based method for disrupting genes across bacteriophage genomes has been developed, creating a faster route to uncover gene functions and engineer phages for potential therapeutic...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
